Tag - CTRV

Developments

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharmaceuticals (NASDAQ:CTRV) announced a name change to Hepion Pharmaceuticals, and a stock symbol change to “HEPA,” effective as of opening of trading on July 23, 2019. “We derived the name “Hepion” by...

July 22, 2019

Developments

ContraVir Pharma sets stage for CRV431 development in NASH with positive results in second model of liver fibrosis

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that CRV431 significantly decreased the extent of fibrosis, or scarring of the liver, in a second animal model of liver fibrosis. CRV431 is a clinical stage cyclophilin...

June 6, 2019

Feature

Robert Foster swinging for the fence again with ContraVir Pharma

Dr. Robert Foster is teeing up another possible home run as the new CEO of ContraVir Pharmaceuticals (NASDAQ:CTRV) and its lead programs for liver disease arising from chronic viral infection and NASH (non-alcoholic...

November 13, 2018

Executive Moves

ContraVir Pharma names biotech industry veteran, Robert Foster, as acting CEO

ContraVir Pharmaceuticals (NASDAQ:CTRV) appointed industry veteran, Robert Foster, as acting CEO, succeeding James Sapirstein.

October 3, 2018

Tag - CTRV

Emerging liver disease company, ContraVir, changes name to Hepion Pharmaceuticals; stock symbol to “HEPA”

ContraVir Pharma sets stage for CRV431 development in NASH with positive results in second model of liver fibrosis

Robert Foster swinging for the fence again with ContraVir Pharma

ContraVir Pharma names biotech industry veteran, Robert Foster, as acting CEO

General

More